Importantly, both macrophage‐specific and systemic inhibition of Runx1 effectively blocked the tumorigenesis of lung cancer in mice; suggesting Runx1 may represent a druggable target for preventing the formation of MMT‐driven tumor‐promoting CAFs in NSCLC. Here, RUNX1 is linked to neoplasm.